BullsEye Insights

BullsEye: Daily London AIM RNS Round-Up

Friday 12 June 2020


Here is our summary of the day's hottest RNS alerts from across London's Alternative Investments Market (AIM).


1Spatial Plc (SPA.LSE)

US$2.6m Contract Win with the US State of Michigan

1Spatial, a global leader in Location Master Data Management (LMDM) software and solutions, announced it has signed a multi-year contract with the State of Michigan in the USA, with an initial total contract value of approximately US$2.6m over five years. The contract builds upon a relationship which began in 2018 and will see the State expand its use of 1Integrate, 1Spatial's data management solution, and combine it with 1Data Gateway, 1Spatial's newly launched portal, to provide an easy to use, automated data submission process for the validation and integration of spatial data from the local level up to the State.  The contract comprises approximately US$1.5m of services, to be delivered in the first two years of the contract, and US$1.1m of software licences, to be recognised over the five years.

This initiative forms an extension of the Michigan Geographic Framework, which created an official base map for State business needs. Over the next five years 1Spatial will be assisting the State with the move to the enterprise 1Integrate platform to support its Spatial Data Infrastructure (SDI) and to extend it to support such efforts as Next Generation 911 (NG911) for emergency management support. Establishing this robust platform will enable Michigan to provide all partners (both State and Local) with a cohesive, integrated single-source of state-wide data. The ability to automate the submission and cleansing of location data submitted across the State by both State and Local entities will enable government to have access to a more robust set of information to utilise for more informed decision support.


For the full RNS, see: https://www.investegate.co.uk/1spatial-plc--spa-/rns/us-2-6m-contract-win-with-the-us-state-of-michigan/202006120700047407P/

Immunodiagnostic Systems Holdings Plc (IDH.LSE)

Automated assay to detect SARS-CoV-2 antibodies

Immunodiagnostic Systems Holdings plc, a specialty solution provider to the clinical laboratory diagnostic market, announced a new automated COVID-19 IgG assay (The Test) has achieved CE marking and is expected to be available for sale by the end of this month. 


The Test, which arises from the partnership between IDS and Technogenetics, is designed to run on the automated IDS-iSYS analyser. Today IDS and Technogenetics reached a commercial agreement under which IDS shall sell, market and support this Test on a global basis.  For territories which do not accept CE marked products, the requisite regulatory approvals will be required.


Test Overview

  • Detects specific IgG antibodies indicating past exposure to the COVID-19 virus and immune response;

  • Quantitative test determines antibody concentration (titer), not just a 'yes/no' result;

  • Highly accurate with a sensitivity of 100%1 and a specificity of 99.4%2, thus meeting the performance criteria specified by MHRA and the Royal College of Pathology, as well as the most common international performance requirements;

  • Test results available within 25 minutes.

Unlike many COVID-19 serology assays currently available, this Test is a quantitative assay. It can determine the antibody concentration in patient serum, rather than giving a 'yes/no' result for prior exposure to the virus. Although the clinical level of functional immunity conferred by SARS-CoV-2 IgG antibodies has not yet been determined, we believe quantitative tests may ultimately be valuable in determining immunity status based on the levels of antibody in the blood.

All steps of the Test are automated with no manual reagent preparation required, ensuring minimal hands-on time for lab staff and a high daily throughput.

IDS-iSYS analysers are already installed in over six hundred laboratories worldwide, including many NHS hospitals. The majority of these analysers are in territories which use the CE mark as the basis for regulatory approval. Each system is capable of running over 10,000 tests per month.


For full RNS details, see: https://www.investegate.co.uk/immunodiagnostic-sys--idh-/rns/automated-assay-to-detect-sars-cov-2-antibodies/202006120700037381P/

Greencoat Renewables Plc (GRP.LSE)

GRP acquires 51.9MW of wind capacity in France

Greencoat Renewables PLC, the renewable infrastructure company invested in euro-dominated assets has completed the acquisition of a 51.9MW portfolio of wind farms in France. Following the acquisition, Greencoat Renewables' total installed capacity will increase to 528.1MW.

The previously announced deal marks the Company's first acquisition in Continental Europe, in line with its strategy to pursue value-accretive assets in specific countries within Europe's very large secondary market.

The portfolio of three windfarms all benefit from France's stable and supportive tariff regime which guarantees a fixed price for the electricity produced by the asset via a Feed in Tariff ("FIT") with a weighted average remaining subsidy life of 12.3 years.

The portfolio of three windfarms come with 16-year long term fixed rate project finance and Greencoat Renewables' total borrowings now represent 43%¹ of Gross Asset Value.


For full RNS details, see: https://www.investegate.co.uk/greencoat-renewables--grp-/rns/grp-acquires-51-9mw-of-wind-capacity-in-france/202006120700037375P/

Download the BullsEye app for your phone or tablet

AppStore.png
playstore.png

*tap here*